When to include clinical study reports and regulatory documents in systematic reviews

Tom Jefferson, Peter Doshi, Isabelle Boutron, Su Golder, Carl Heneghan, Alex Hodkinson, Mark Jones, Carol Lefebvre, Lesley A. Stewart

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Reporting bias is a major threat to the validity and credibility of systematic reviews. This article outlines the rationale for accessing clinical study reports and other regulatory documents (regulatory data) as a means of addressing reporting bias and identifies factors that may help decide whether (or not) to include regulatory data in systematic reviews. The article also describes the origins and current state of regulatory data access and summarises a survey of current systematic reviewers' practices in considering regulatory data for inclusion in systematic reviews. How to access and extract regulatory data is not addressed. Organisations and other stakeholders such as Cochrane should encourage the use of data from clinical study reports as an important source of data in reviews of pharmaceutical interventions particularly when the intervention in question is of high importance and the risk of reporting bias is great.

Original languageEnglish
JournalBMJ Evidence-Based Medicine
Volume23
Issue number6
DOIs
Publication statusPublished - 1 Jan 2018
Externally publishedYes

Fingerprint

Information Storage and Retrieval
Pharmaceutical Preparations
Clinical Studies
Surveys and Questionnaires

Cite this

Jefferson, T., Doshi, P., Boutron, I., Golder, S., Heneghan, C., Hodkinson, A., ... Stewart, L. A. (2018). When to include clinical study reports and regulatory documents in systematic reviews. BMJ Evidence-Based Medicine, 23(6). https://doi.org/10.1136/bmjebm-2018-110963
Jefferson, Tom ; Doshi, Peter ; Boutron, Isabelle ; Golder, Su ; Heneghan, Carl ; Hodkinson, Alex ; Jones, Mark ; Lefebvre, Carol ; Stewart, Lesley A. / When to include clinical study reports and regulatory documents in systematic reviews. In: BMJ Evidence-Based Medicine. 2018 ; Vol. 23, No. 6.
@article{61265f688e9b46d6b208e2de4f10fe76,
title = "When to include clinical study reports and regulatory documents in systematic reviews",
abstract = "Reporting bias is a major threat to the validity and credibility of systematic reviews. This article outlines the rationale for accessing clinical study reports and other regulatory documents (regulatory data) as a means of addressing reporting bias and identifies factors that may help decide whether (or not) to include regulatory data in systematic reviews. The article also describes the origins and current state of regulatory data access and summarises a survey of current systematic reviewers' practices in considering regulatory data for inclusion in systematic reviews. How to access and extract regulatory data is not addressed. Organisations and other stakeholders such as Cochrane should encourage the use of data from clinical study reports as an important source of data in reviews of pharmaceutical interventions particularly when the intervention in question is of high importance and the risk of reporting bias is great.",
author = "Tom Jefferson and Peter Doshi and Isabelle Boutron and Su Golder and Carl Heneghan and Alex Hodkinson and Mark Jones and Carol Lefebvre and Stewart, {Lesley A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/bmjebm-2018-110963",
language = "English",
volume = "23",
journal = "Evidence-Based Medicine",
issn = "1356-5524",
publisher = "BMJ Publishing Group",
number = "6",

}

Jefferson, T, Doshi, P, Boutron, I, Golder, S, Heneghan, C, Hodkinson, A, Jones, M, Lefebvre, C & Stewart, LA 2018, 'When to include clinical study reports and regulatory documents in systematic reviews' BMJ Evidence-Based Medicine, vol. 23, no. 6. https://doi.org/10.1136/bmjebm-2018-110963

When to include clinical study reports and regulatory documents in systematic reviews. / Jefferson, Tom; Doshi, Peter; Boutron, Isabelle; Golder, Su; Heneghan, Carl; Hodkinson, Alex; Jones, Mark; Lefebvre, Carol; Stewart, Lesley A.

In: BMJ Evidence-Based Medicine, Vol. 23, No. 6, 01.01.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - When to include clinical study reports and regulatory documents in systematic reviews

AU - Jefferson, Tom

AU - Doshi, Peter

AU - Boutron, Isabelle

AU - Golder, Su

AU - Heneghan, Carl

AU - Hodkinson, Alex

AU - Jones, Mark

AU - Lefebvre, Carol

AU - Stewart, Lesley A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Reporting bias is a major threat to the validity and credibility of systematic reviews. This article outlines the rationale for accessing clinical study reports and other regulatory documents (regulatory data) as a means of addressing reporting bias and identifies factors that may help decide whether (or not) to include regulatory data in systematic reviews. The article also describes the origins and current state of regulatory data access and summarises a survey of current systematic reviewers' practices in considering regulatory data for inclusion in systematic reviews. How to access and extract regulatory data is not addressed. Organisations and other stakeholders such as Cochrane should encourage the use of data from clinical study reports as an important source of data in reviews of pharmaceutical interventions particularly when the intervention in question is of high importance and the risk of reporting bias is great.

AB - Reporting bias is a major threat to the validity and credibility of systematic reviews. This article outlines the rationale for accessing clinical study reports and other regulatory documents (regulatory data) as a means of addressing reporting bias and identifies factors that may help decide whether (or not) to include regulatory data in systematic reviews. The article also describes the origins and current state of regulatory data access and summarises a survey of current systematic reviewers' practices in considering regulatory data for inclusion in systematic reviews. How to access and extract regulatory data is not addressed. Organisations and other stakeholders such as Cochrane should encourage the use of data from clinical study reports as an important source of data in reviews of pharmaceutical interventions particularly when the intervention in question is of high importance and the risk of reporting bias is great.

UR - http://www.scopus.com/inward/record.url?scp=85054922091&partnerID=8YFLogxK

U2 - 10.1136/bmjebm-2018-110963

DO - 10.1136/bmjebm-2018-110963

M3 - Article

VL - 23

JO - Evidence-Based Medicine

JF - Evidence-Based Medicine

SN - 1356-5524

IS - 6

ER -